Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Giampaolo Bianchini, Astrid Kiermaier, Giulia Valeria Bianchi, Young-Hyuck Im, Tadeusz Pienkowski, Mei-Ching Liu, Ling-Ming Tseng, Mitch Dowsett, Lila Zabaglo, Sarah Kirk, Tania Szado, Jennifer Eng-Wong, Lukas C. Amler, Pinuccia Valagussa, Luca Gianni

ABSTRACT

BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth factor receptor 2 (HER2) pathway-related biomarkers and clinical outcome in response to these regimens. METHODS: Tumor, serum, and whole blood samples were collected at baseline and post neoadjuvant treatment before surgery. Associations between biomarkers and pCR, and between biomarkers and clinical variables were assessed in the overall and estrogen receptor (ER)-positive and ER-negative populations. Changes in serum marker levels between baseline and post-neoadjuvant treatment were examined. RESULTS: No markers were associated with pCR across all groups; however, significant associations were observed for two markers in individual groups. High HER2 was significantly associated with higher pCR rates (P = 0.001) and a significant treatment interaction (P = 0.0236) with pertuzumab, trastuzumab, and docetaxel (odds ratio 2.07, P = 0.01). Low serum transforming growth factor alpha (TGFα) was associated with higher pCR rates with pertuzumab plus trastuzumab (P = 0.04) without a significant treatment interaction. Presence of truncated HER2 did not affect pCR. A non-significant decreased pCR benefit was observed consistently across groups in patients with mutated PIK3CA while the treatment benefit from pertuzumab was maintained when comparing the trastuzumab plus docetaxel and pertuzumab, trastuzumab, and docetaxel groups. Notably, PIK3CA exon 9 mutations were associated with residual disease (pooled groups), which was not found for exon 20 mutations. Serum HER2 extracellular domain levels were significantly increased between baseline and post-neoadjuvant treatment in the non-trastuzumab-treated group, and decreased in the trastuzumab-containing groups (likely due to trastuzumab's mechanism of action). Differences in biomarker profiles according to ER status were observed. CONCLUSIONS: The observed associations of HER2 protein levels with sensitivity to pertuzumab, and of PIK3CA exon 9 mutation to lack of sensitivity to HER2-targeted monoclonal antibody treatment, warrant further investigation. Previously reported findings of truncated forms of HER2 as resistance markers to HER2-targeted treatment could not be confirmed in NeoSphere. Conventional HER2 assessment should continue and HER2 remains the only biomarker suitable for patient selection in this population. TRIAL REGISTRATION: Clinicaltrials.gov, NCT00545688 . Registered on 16 October 2007. More... »

PAGES

16

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13058-017-0806-9

DOI

http://dx.doi.org/10.1186/s13058-017-0806-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1083737882

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28183321


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Oncologia Medica, Ospedale San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bianchini", 
        "givenName": "Giampaolo", 
        "id": "sg:person.01154173453.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154173453.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "Genentech, Inc., Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kiermaier", 
        "givenName": "Astrid", 
        "id": "sg:person.01170473442.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170473442.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituto Nazionale dei Tumori", 
          "id": "https://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bianchi", 
        "givenName": "Giulia Valeria", 
        "id": "sg:person.013530046122.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013530046122.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Samsung Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.414964.a", 
          "name": [
            "Samsung Medical Center, Seoul, Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Im", 
        "givenName": "Young-Hyuck", 
        "id": "sg:person.01051352243.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051352243.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Postgraduate Medical Education Center, Warsaw, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pienkowski", 
        "givenName": "Tadeusz", 
        "id": "sg:person.01372307334.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372307334.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Koo Foundation Sun Yat-Sen Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.418962.0", 
          "name": [
            "Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Mei-Ching", 
        "id": "sg:person.01053554560.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053554560.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tseng", 
        "givenName": "Ling-Ming", 
        "id": "sg:person.013562536337.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013562536337.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Centre for Molecular Pathology, Royal Marsden Hospital, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dowsett", 
        "givenName": "Mitch", 
        "id": "sg:person.015776405257.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015776405257.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "Institute of Cancer Research, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zabaglo", 
        "givenName": "Lila", 
        "id": "sg:person.01047202751.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047202751.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products Limited, Welwyn, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kirk", 
        "givenName": "Sarah", 
        "id": "sg:person.010425012427.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010425012427.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Szado", 
        "givenName": "Tania", 
        "id": "sg:person.01345441500.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345441500.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eng-Wong", 
        "givenName": "Jennifer", 
        "id": "sg:person.01133443573.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133443573.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418158.1", 
          "name": [
            "Genentech, Inc., South San Francisco, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amler", 
        "givenName": "Lukas C.", 
        "id": "sg:person.0743464601.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743464601.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fondazione Michelangelo", 
          "id": "https://www.grid.ac/institutes/grid.476276.6", 
          "name": [
            "Fondazione Michelangelo, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valagussa", 
        "givenName": "Pinuccia", 
        "id": "sg:person.0715002305.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715002305.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Oncologia Medica, Ospedale San Raffaele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gianni", 
        "givenName": "Luca", 
        "id": "sg:person.01351442324.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351442324.69"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s1535-6108(04)00083-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002635571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/95.2.142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005473380"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-03-3856", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006401030"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-03-3856", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006401030"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70336-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006777850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.54.5384", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007271230"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1535-6108(02)00097-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009224253"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1113216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013126608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-06-0766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015864890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016084928"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-15-2499", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017320489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-05-1807", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018979654"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(08)70544-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037090583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)61964-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038345999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ajpath.2013.04.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038822565"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1413513", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043562849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61847-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043834514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.03.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048708034"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdt182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049729330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0712169105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051908274"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-08-4597", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053676255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.11.069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074834930", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth factor receptor 2 (HER2) pathway-related biomarkers and clinical outcome in response to these regimens.\nMETHODS: Tumor, serum, and whole blood samples were collected at baseline and post neoadjuvant treatment before surgery. Associations between biomarkers and pCR, and between biomarkers and clinical variables were assessed in the overall and estrogen receptor (ER)-positive and ER-negative populations. Changes in serum marker levels between baseline and post-neoadjuvant treatment were examined.\nRESULTS: No markers were associated with pCR across all groups; however, significant associations were observed for two markers in individual groups. High HER2 was significantly associated with higher pCR rates (P\u2009=\u20090.001) and a significant treatment interaction (P\u2009=\u20090.0236) with pertuzumab, trastuzumab, and docetaxel (odds ratio 2.07, P\u2009=\u20090.01). Low serum transforming growth factor alpha (TGF\u03b1) was associated with higher pCR rates with pertuzumab plus trastuzumab (P\u2009=\u20090.04) without a significant treatment interaction. Presence of truncated HER2 did not affect pCR. A non-significant decreased pCR benefit was observed consistently across groups in patients with mutated PIK3CA while the treatment benefit from pertuzumab was maintained when comparing the trastuzumab plus docetaxel and pertuzumab, trastuzumab, and docetaxel groups. Notably, PIK3CA exon 9 mutations were associated with residual disease (pooled groups), which was not found for exon 20 mutations. Serum HER2 extracellular domain levels were significantly increased between baseline and post-neoadjuvant treatment in the non-trastuzumab-treated group, and decreased in the trastuzumab-containing groups (likely due to trastuzumab's mechanism of action). Differences in biomarker profiles according to ER status were observed.\nCONCLUSIONS: The observed associations of HER2 protein levels with sensitivity to pertuzumab, and of PIK3CA exon 9 mutation to lack of sensitivity to HER2-targeted monoclonal antibody treatment, warrant further investigation. Previously reported findings of truncated forms of HER2 as resistance markers to HER2-targeted treatment could not be confirmed in NeoSphere. Conventional HER2 assessment should continue and HER2 remains the only biomarker suitable for patient selection in this population.\nTRIAL REGISTRATION: Clinicaltrials.gov, NCT00545688 . Registered on 16 October 2007.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13058-017-0806-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1022375", 
        "issn": [
          "1465-5411", 
          "1465-542X"
        ], 
        "name": "Breast Cancer Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer", 
    "pagination": "16", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "67dc229ce8c3508082b9175c2dc370f4901571013d9e5162644aa71672edfd07"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28183321"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100927353"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13058-017-0806-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1083737882"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13058-017-0806-9", 
      "https://app.dimensions.ai/details/publication/pub.1083737882"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89798_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13058-017-0806-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13058-017-0806-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13058-017-0806-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13058-017-0806-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13058-017-0806-9'


 

This table displays all metadata directly associated to this object as RDF triples.

323 TRIPLES      21 PREDICATES      66 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13058-017-0806-9 schema:about N0788161b73d84df8a454978ba2d8e595
2 N0caddec1bcc24a41bd335dd1ae296fef
3 N39799b52e4ad41359d684f1a6c20a203
4 N448c9bb191fd439b8c7a14db9074a044
5 N5d12a9dababe41818bd17ab0c69a3156
6 N647435dbfcf147c7b6fdc658f311ce01
7 N7752cce1c38044869413ad7f956ba2ce
8 N8cea8cc38b774e95847418aea3503b65
9 N92383e2abb7142659c37b5b796d7df8f
10 Na21160a7d88e461bb6eb8bdb92a68669
11 Nb45bc29c8c9342f7a1abf2e2eee73362
12 Nbceb2ccd91974309ae773b89e534d093
13 Neb4d9937c9164673b0b6b43690e9c52e
14 Nf974638692a641a5860bb2b6e4dc1fba
15 Nfc2c09c2b0ea4c0482371f8de72ac2b0
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Nde638c56f8ea4d72b028e3eae4609145
19 schema:citation https://app.dimensions.ai/details/publication/pub.1074834930
20 https://doi.org/10.1016/j.ajpath.2013.04.010
21 https://doi.org/10.1016/j.ccr.2009.03.020
22 https://doi.org/10.1016/s0140-6736(09)61964-4
23 https://doi.org/10.1016/s0140-6736(11)61847-3
24 https://doi.org/10.1016/s1359-6349(08)70544-5
25 https://doi.org/10.1016/s1470-2045(11)70336-9
26 https://doi.org/10.1016/s1535-6108(02)00097-1
27 https://doi.org/10.1016/s1535-6108(04)00083-2
28 https://doi.org/10.1056/nejmoa1113216
29 https://doi.org/10.1056/nejmoa1413513
30 https://doi.org/10.1073/pnas.0712169105
31 https://doi.org/10.1093/annonc/mdt182
32 https://doi.org/10.1093/annonc/mdt275
33 https://doi.org/10.1093/jnci/95.2.142
34 https://doi.org/10.1158/0008-5472.can-03-3856
35 https://doi.org/10.1158/0008-5472.can-08-4597
36 https://doi.org/10.1158/1078-0432.ccr-05-1807
37 https://doi.org/10.1158/1078-0432.ccr-15-2499
38 https://doi.org/10.1158/1535-7163.mct-06-0766
39 https://doi.org/10.1200/jco.2003.11.069
40 https://doi.org/10.1200/jco.2013.54.5384
41 schema:datePublished 2017-12
42 schema:datePublishedReg 2017-12-01
43 schema:description BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth factor receptor 2 (HER2) pathway-related biomarkers and clinical outcome in response to these regimens. METHODS: Tumor, serum, and whole blood samples were collected at baseline and post neoadjuvant treatment before surgery. Associations between biomarkers and pCR, and between biomarkers and clinical variables were assessed in the overall and estrogen receptor (ER)-positive and ER-negative populations. Changes in serum marker levels between baseline and post-neoadjuvant treatment were examined. RESULTS: No markers were associated with pCR across all groups; however, significant associations were observed for two markers in individual groups. High HER2 was significantly associated with higher pCR rates (P = 0.001) and a significant treatment interaction (P = 0.0236) with pertuzumab, trastuzumab, and docetaxel (odds ratio 2.07, P = 0.01). Low serum transforming growth factor alpha (TGFα) was associated with higher pCR rates with pertuzumab plus trastuzumab (P = 0.04) without a significant treatment interaction. Presence of truncated HER2 did not affect pCR. A non-significant decreased pCR benefit was observed consistently across groups in patients with mutated PIK3CA while the treatment benefit from pertuzumab was maintained when comparing the trastuzumab plus docetaxel and pertuzumab, trastuzumab, and docetaxel groups. Notably, PIK3CA exon 9 mutations were associated with residual disease (pooled groups), which was not found for exon 20 mutations. Serum HER2 extracellular domain levels were significantly increased between baseline and post-neoadjuvant treatment in the non-trastuzumab-treated group, and decreased in the trastuzumab-containing groups (likely due to trastuzumab's mechanism of action). Differences in biomarker profiles according to ER status were observed. CONCLUSIONS: The observed associations of HER2 protein levels with sensitivity to pertuzumab, and of PIK3CA exon 9 mutation to lack of sensitivity to HER2-targeted monoclonal antibody treatment, warrant further investigation. Previously reported findings of truncated forms of HER2 as resistance markers to HER2-targeted treatment could not be confirmed in NeoSphere. Conventional HER2 assessment should continue and HER2 remains the only biomarker suitable for patient selection in this population. TRIAL REGISTRATION: Clinicaltrials.gov, NCT00545688 . Registered on 16 October 2007.
44 schema:genre research_article
45 schema:inLanguage en
46 schema:isAccessibleForFree true
47 schema:isPartOf N2132d09324a747ac810490bb9bb7ff59
48 Nf68da086d8eb4d92aeb164827c17d016
49 sg:journal.1022375
50 schema:name Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
51 schema:pagination 16
52 schema:productId N6516699c5b074fcd8e4781f08e011e72
53 N7b28dffa12b04c5c95513790e236fa3c
54 Nb215e4991df94d639856b51460caf44a
55 Nd466383b745349b9a62476f72d23eaf6
56 Nf88e7837a009437e9b309a77c6c4e81b
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083737882
58 https://doi.org/10.1186/s13058-017-0806-9
59 schema:sdDatePublished 2019-04-11T09:54
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher N9d7a95a90fe54ccf8a40031a374b1961
62 schema:url https://link.springer.com/10.1186%2Fs13058-017-0806-9
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N0788161b73d84df8a454978ba2d8e595 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Mutation
68 rdf:type schema:DefinedTerm
69 N0caddec1bcc24a41bd335dd1ae296fef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Trastuzumab
71 rdf:type schema:DefinedTerm
72 N1059eb82c0024ae9aba38d253e82975b rdf:first sg:person.0743464601.71
73 rdf:rest N8633fbc0209a466d97119ff14283c210
74 N163c545baa844ff8b0aed38302488513 rdf:first sg:person.010425012427.35
75 rdf:rest Nb6efbb4a810844f7a358f3b9886f8e89
76 N2132d09324a747ac810490bb9bb7ff59 schema:volumeNumber 19
77 rdf:type schema:PublicationVolume
78 N33d37fbfd7334fcca34b5c732a763d46 rdf:first sg:person.013530046122.37
79 rdf:rest Nc6a07532339547f499b0f631413c6275
80 N39799b52e4ad41359d684f1a6c20a203 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Docetaxel
82 rdf:type schema:DefinedTerm
83 N409228b9963d416aa29d0e5effdc4c15 rdf:first sg:person.01053554560.36
84 rdf:rest N4ae5bbb21e3249c59ecdd4b9979ac9f2
85 N448c9bb191fd439b8c7a14db9074a044 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Antibodies, Monoclonal, Humanized
87 rdf:type schema:DefinedTerm
88 N4ae5bbb21e3249c59ecdd4b9979ac9f2 rdf:first sg:person.013562536337.96
89 rdf:rest Ndf10974845f642439341c2696d1e1d46
90 N513e6da9a9244e8db1bd7c5719b21ceb rdf:first sg:person.01133443573.01
91 rdf:rest N1059eb82c0024ae9aba38d253e82975b
92 N5a03f5e8367b46b4ba4d14ad23a7aa4b schema:name Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan, Republic of China
93 rdf:type schema:Organization
94 N5d12a9dababe41818bd17ab0c69a3156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Treatment Outcome
96 rdf:type schema:DefinedTerm
97 N5de840dfe02e4775890f4cc33174dcaa rdf:first sg:person.01047202751.66
98 rdf:rest N163c545baa844ff8b0aed38302488513
99 N647435dbfcf147c7b6fdc658f311ce01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Biomarkers
101 rdf:type schema:DefinedTerm
102 N6516699c5b074fcd8e4781f08e011e72 schema:name pubmed_id
103 schema:value 28183321
104 rdf:type schema:PropertyValue
105 N73ebc74a5aad46deadd6dba0437834fb rdf:first sg:person.01372307334.38
106 rdf:rest N409228b9963d416aa29d0e5effdc4c15
107 N74e3ecb2ff1c424189982a411c3c0ef0 rdf:first sg:person.01351442324.69
108 rdf:rest rdf:nil
109 N7752cce1c38044869413ad7f956ba2ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Female
111 rdf:type schema:DefinedTerm
112 N7b28dffa12b04c5c95513790e236fa3c schema:name nlm_unique_id
113 schema:value 100927353
114 rdf:type schema:PropertyValue
115 N8633fbc0209a466d97119ff14283c210 rdf:first sg:person.0715002305.49
116 rdf:rest N74e3ecb2ff1c424189982a411c3c0ef0
117 N8cea8cc38b774e95847418aea3503b65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Immunohistochemistry
119 rdf:type schema:DefinedTerm
120 N92383e2abb7142659c37b5b796d7df8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Biomarkers, Tumor
122 rdf:type schema:DefinedTerm
123 N9d7a95a90fe54ccf8a40031a374b1961 schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 Na21160a7d88e461bb6eb8bdb92a68669 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Receptor, ErbB-2
127 rdf:type schema:DefinedTerm
128 Nb215e4991df94d639856b51460caf44a schema:name readcube_id
129 schema:value 67dc229ce8c3508082b9175c2dc370f4901571013d9e5162644aa71672edfd07
130 rdf:type schema:PropertyValue
131 Nb45bc29c8c9342f7a1abf2e2eee73362 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Breast Neoplasms
133 rdf:type schema:DefinedTerm
134 Nb6efbb4a810844f7a358f3b9886f8e89 rdf:first sg:person.01345441500.28
135 rdf:rest N513e6da9a9244e8db1bd7c5719b21ceb
136 Nbceb2ccd91974309ae773b89e534d093 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Neoadjuvant Therapy
138 rdf:type schema:DefinedTerm
139 Nc6a07532339547f499b0f631413c6275 rdf:first sg:person.01051352243.36
140 rdf:rest N73ebc74a5aad46deadd6dba0437834fb
141 Nd08fc45861064da6af1799e5676dc2f5 schema:name Postgraduate Medical Education Center, Warsaw, Poland
142 rdf:type schema:Organization
143 Nd466383b745349b9a62476f72d23eaf6 schema:name dimensions_id
144 schema:value pub.1083737882
145 rdf:type schema:PropertyValue
146 Nde638c56f8ea4d72b028e3eae4609145 rdf:first sg:person.01154173453.97
147 rdf:rest Nfb533894afdb455298333c49eb75d148
148 Ndf10974845f642439341c2696d1e1d46 rdf:first sg:person.015776405257.84
149 rdf:rest N5de840dfe02e4775890f4cc33174dcaa
150 Neb4d9937c9164673b0b6b43690e9c52e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antineoplastic Combined Chemotherapy Protocols
152 rdf:type schema:DefinedTerm
153 Nf68da086d8eb4d92aeb164827c17d016 schema:issueNumber 1
154 rdf:type schema:PublicationIssue
155 Nf88e7837a009437e9b309a77c6c4e81b schema:name doi
156 schema:value 10.1186/s13058-017-0806-9
157 rdf:type schema:PropertyValue
158 Nf974638692a641a5860bb2b6e4dc1fba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Humans
160 rdf:type schema:DefinedTerm
161 Nfb533894afdb455298333c49eb75d148 rdf:first sg:person.01170473442.74
162 rdf:rest N33d37fbfd7334fcca34b5c732a763d46
163 Nfc2c09c2b0ea4c0482371f8de72ac2b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Taxoids
165 rdf:type schema:DefinedTerm
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
170 schema:name Oncology and Carcinogenesis
171 rdf:type schema:DefinedTerm
172 sg:journal.1022375 schema:issn 1465-5411
173 1465-542X
174 schema:name Breast Cancer Research
175 rdf:type schema:Periodical
176 sg:person.010425012427.35 schema:affiliation https://www.grid.ac/institutes/grid.419227.b
177 schema:familyName Kirk
178 schema:givenName Sarah
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010425012427.35
180 rdf:type schema:Person
181 sg:person.01047202751.66 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
182 schema:familyName Zabaglo
183 schema:givenName Lila
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047202751.66
185 rdf:type schema:Person
186 sg:person.01051352243.36 schema:affiliation https://www.grid.ac/institutes/grid.414964.a
187 schema:familyName Im
188 schema:givenName Young-Hyuck
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051352243.36
190 rdf:type schema:Person
191 sg:person.01053554560.36 schema:affiliation https://www.grid.ac/institutes/grid.418962.0
192 schema:familyName Liu
193 schema:givenName Mei-Ching
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053554560.36
195 rdf:type schema:Person
196 sg:person.01133443573.01 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
197 schema:familyName Eng-Wong
198 schema:givenName Jennifer
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133443573.01
200 rdf:type schema:Person
201 sg:person.01154173453.97 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
202 schema:familyName Bianchini
203 schema:givenName Giampaolo
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154173453.97
205 rdf:type schema:Person
206 sg:person.01170473442.74 schema:affiliation https://www.grid.ac/institutes/grid.417570.0
207 schema:familyName Kiermaier
208 schema:givenName Astrid
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170473442.74
210 rdf:type schema:Person
211 sg:person.01345441500.28 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
212 schema:familyName Szado
213 schema:givenName Tania
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345441500.28
215 rdf:type schema:Person
216 sg:person.01351442324.69 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
217 schema:familyName Gianni
218 schema:givenName Luca
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351442324.69
220 rdf:type schema:Person
221 sg:person.013530046122.37 schema:affiliation https://www.grid.ac/institutes/grid.417893.0
222 schema:familyName Bianchi
223 schema:givenName Giulia Valeria
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013530046122.37
225 rdf:type schema:Person
226 sg:person.013562536337.96 schema:affiliation N5a03f5e8367b46b4ba4d14ad23a7aa4b
227 schema:familyName Tseng
228 schema:givenName Ling-Ming
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013562536337.96
230 rdf:type schema:Person
231 sg:person.01372307334.38 schema:affiliation Nd08fc45861064da6af1799e5676dc2f5
232 schema:familyName Pienkowski
233 schema:givenName Tadeusz
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372307334.38
235 rdf:type schema:Person
236 sg:person.015776405257.84 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
237 schema:familyName Dowsett
238 schema:givenName Mitch
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015776405257.84
240 rdf:type schema:Person
241 sg:person.0715002305.49 schema:affiliation https://www.grid.ac/institutes/grid.476276.6
242 schema:familyName Valagussa
243 schema:givenName Pinuccia
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715002305.49
245 rdf:type schema:Person
246 sg:person.0743464601.71 schema:affiliation https://www.grid.ac/institutes/grid.418158.1
247 schema:familyName Amler
248 schema:givenName Lukas C.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743464601.71
250 rdf:type schema:Person
251 https://app.dimensions.ai/details/publication/pub.1074834930 schema:CreativeWork
252 https://doi.org/10.1016/j.ajpath.2013.04.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038822565
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/j.ccr.2009.03.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048708034
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/s0140-6736(09)61964-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038345999
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1016/s0140-6736(11)61847-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043834514
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1016/s1359-6349(08)70544-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037090583
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1016/s1470-2045(11)70336-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006777850
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1016/s1535-6108(02)00097-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009224253
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/s1535-6108(04)00083-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002635571
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1056/nejmoa1113216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013126608
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1056/nejmoa1413513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043562849
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1073/pnas.0712169105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051908274
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1093/annonc/mdt182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049729330
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1093/annonc/mdt275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016084928
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1093/jnci/95.2.142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005473380
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1158/0008-5472.can-03-3856 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006401030
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1158/0008-5472.can-08-4597 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053676255
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1158/1078-0432.ccr-05-1807 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018979654
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1158/1078-0432.ccr-15-2499 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017320489
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1158/1535-7163.mct-06-0766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015864890
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1200/jco.2003.11.069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203957
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1200/jco.2013.54.5384 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007271230
293 rdf:type schema:CreativeWork
294 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
295 schema:name Institute of Cancer Research, London, UK
296 rdf:type schema:Organization
297 https://www.grid.ac/institutes/grid.18887.3e schema:alternateName San Raffaele Hospital
298 schema:name Oncologia Medica, Ospedale San Raffaele, Milan, Italy
299 rdf:type schema:Organization
300 https://www.grid.ac/institutes/grid.414964.a schema:alternateName Samsung Medical Center
301 schema:name Samsung Medical Center, Seoul, Korea
302 rdf:type schema:Organization
303 https://www.grid.ac/institutes/grid.417570.0 schema:alternateName Roche (Switzerland)
304 schema:name Genentech, Inc., Basel, Switzerland
305 rdf:type schema:Organization
306 https://www.grid.ac/institutes/grid.417893.0 schema:alternateName Istituto Nazionale dei Tumori
307 schema:name Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
308 rdf:type schema:Organization
309 https://www.grid.ac/institutes/grid.418158.1 schema:alternateName Roche (United States)
310 schema:name Genentech, Inc., South San Francisco, CA, USA
311 rdf:type schema:Organization
312 https://www.grid.ac/institutes/grid.418962.0 schema:alternateName Koo Foundation Sun Yat-Sen Cancer Center
313 schema:name Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, Republic of China
314 rdf:type schema:Organization
315 https://www.grid.ac/institutes/grid.419227.b schema:alternateName Roche (United Kingdom)
316 schema:name Roche Products Limited, Welwyn, UK
317 rdf:type schema:Organization
318 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
319 schema:name Centre for Molecular Pathology, Royal Marsden Hospital, London, UK
320 rdf:type schema:Organization
321 https://www.grid.ac/institutes/grid.476276.6 schema:alternateName Fondazione Michelangelo
322 schema:name Fondazione Michelangelo, Milan, Italy
323 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...